|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
30.0 |
106.61 |
| DMSO |
65.0 |
230.99 |
| Ethanol |
30.0 |
106.61 |
| Ethanol:PBS (pH 7.2) (1:1) |
0.5 |
1.78 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
281.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Oleson EB, Ferris MJ, España RA, Harp J, Jones SR. Effects of the histamine H₁ receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward. Eur J Pharmacol. 2012 May 15;683(1-3):161-5. doi: 10.1016/j.ejphar.2012.03.003. Epub 2012 Mar 15. PubMed PMID: 22445882; PubMed Central PMCID: PMC3340496.
2: Montijo-Barrios E, Cadena F, Ramírez-Mayans JA, Gutiérrez-Castrellón P. [Clinical trial on the effect of buphenine, aminophenazone and diphenylpyraline hydrochloride in treating the common cold in children of 6 to 24 months of age]. Rev Invest Clin. 2011 Jul-Aug;63(4):335-43. Spanish. PubMed PMID: 22364032.
3: Weis R, Faist J, di Vora U, Schweiger K, Brandner B, Kungl AJ, Seebacher W. Antimycobacterial activity of diphenylpyraline derivatives. Eur J Med Chem. 2008 Apr;43(4):872-9. Epub 2007 Jul 10. PubMed PMID: 17714832.
4: Shakleya DM, Jansson LM, Huestis MA. Validation of a LC-APCI-MS/MS method for quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyraline (EMDP) in infant plasma following protein precipitation. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):267-72. Epub 2007 Jun 16. PubMed PMID: 17602899.
5: Choo RE, Murphy CM, Jones HE, Huestis MA. Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, 2-ethyl-5-methyl-3,3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jan 25;814(2):369-73. PubMed PMID: 15639461.
6: Lapa GB, Mathews TA, Harp J, Budygin EA, Jones SR. Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties. Eur J Pharmacol. 2005 Jan 4;506(3):237-40. Epub 2004 Dec 8. PubMed PMID: 15627433.
7: Puhakka H, Rantanen T, Virolainen E. Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis. J Int Med Res. 1977;5(1):37-41. PubMed PMID: 14039.
8: KNOCHE C, KOENIG J. [ON THE PRENATAL TOXICITY OF DIPHENYLPYRALINE 8-CHLOROTHEOPHYLLINATE WITH REFERENCE TO EXPERIENCES WITH THALIDOMIDE AND CAFFEINE]. Arzneimittelforschung. 1964 May;14:415-24. German. PubMed PMID: 14238604.
9: ANDRE J, EILARD U, HELLGREN L. [Diphenylpyraline HCl (Histyn) in long-acting preparations (Durettes) in hay fever]. Sven Lakartidn. 1961 Apr 28;58:1245-9. Swedish. PubMed PMID: 13683344.
10: HELFAND AE. Clinical evaluation of "diphenylpyraline" as an antifungal agent in tinea pedis. A preliminary report. J Am Podiatry Assoc. 1961 Feb;51:109-11. PubMed PMID: 13713076.
11: NACHTIGALL HB. Clinical evaluation of diphenylpyraline. J Allergy. 1956 Jan;27(1):75-7. PubMed PMID: 13294977.
12: VAN DE ERVE J Jr. Fungicidal activity of diphenylpyraline. AMA Arch Derm Syphilol. 1953 Nov;68(5):572-4. PubMed PMID: 13091417.
13: Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I. Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci. 2001 Jan 1;182(2):95-7. PubMed PMID: 11137513.
14: Vasudevan M, Ravisankar S, Sathiyanarayanan A, Chandan RS. Simultaneous estimation of phenylpropanolamine HCl, guaiphenesin and diphenylpyraline HCl in syrups by LC. J Pharm Biomed Anal. 2000 Dec;24(1):25-31. PubMed PMID: 11108536.
15: Ebete KO, Koundourellis JE. Determination of diphenylpyraline in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Mar 3;677(2):319-23. PubMed PMID: 8704936.
16: de Fabrizio F. GLC analysis of theophylline, hydroxyethyltheophylline, and diphenylpyraline hydrochloride syrup. J Pharm Sci. 1979 Apr;68(4):521-2. PubMed PMID: 35600.
17: Graham G, Bolt AG. Half-life of diphenylpyraline in man. J Pharmacokinet Biopharm. 1974 Jun;2(3):191-5. PubMed PMID: 4156058.
18: Kuokkanen K, Paavilainen O. Evaluation of slow-releasing diphenylpyraline in chronic urticaria and various kinds of dermatites. Acta Allergol. 1971 Dec;26(6):454-62. PubMed PMID: 4401352.
19: PADBERG G. [BIOCHEMICAL STUDIES ON THE MATURATION OF FETAL CONNECTIVE TISSUE UNDER THE INFLUENCE OF DIPHENYLPYRALINE-8-CHLOROTHEOPHYLLINATE AND CAFFEINE]. Arzneimittelforschung. 1964 May;14:424-8. German. PubMed PMID: 14238605.
20: FARRERONS-CO J. [Present status of antihistamine therapy. Clinical evaluation of diphenylpyraline]. Med Clin (Barc). 1962 Nov;39:346-50. Spanish. PubMed PMID: 13944461.
